What Доцетаксел treats: Main Uses and Benefits

Docetaxel is used as a systemic therapy for a range of established malignant neoplasms, including advanced breast cancer, prostate cancer, non-small cell lung cancer, gastric adenocarcinoma, and squamous cell carcinoma of the head and neck. Docetaxel is applied in therapeutic domains involving conditions presenting with systemic or localized discomfort and heightened physiological stress. The medication is commonly used as adjuvant therapy in high-risk conditions and is applied in refractory settings after prior symptomatic management.

---

“This supportive therapy is relevant in contexts involving heightened systemic burden, assisting with maintaining functional stability.”

---

In situations where patients experience these challenging cancer-related symptoms (symptoms related to physical discomfort), Docetaxel assists with maintaining functional stability and supports general well-being during symptomatic phases. Its goal is to provide supportive therapy that helps ease the overall symptom burden.

---

Quick Fact: Support for Conditions Involving Systemic Discomfort
Primary Therapeutic Goal: Support maintenance of functional stability in advanced conditions.
Common Scenarios: Adjuvant use for managing symptoms related to systemic imbalance, or treatment of refractory prostate cancer.
Key Patient Benefit: Contributes to improved comfort during periods of heightened symptoms.

Who Can and Cannot Use Docetaxel

Eligibility for Docetaxel is strictly determined by regulatory criteria, focusing on patient status and specific pre-existing conditions. Use is contraindicated in several mandatory exclusion categories.

---

Contraindications and Non-Eligibility

Docetaxel must not be used in patients with a history of severe hypersensitivity reactions to the drug itself or to products containing the excipient Polysorbate 80. It is also formally contraindicated for patients with severe hepatic impairment, defined by specific laboratory thresholds for bilirubin and liver enzymes, or those with a baseline neutrophil count of less than 1,500 cells/mm^3.

---

Special Population Restrictions

Population Group	Regulatory Status
Pregnancy	Contraindicated (Can cause fetal harm).
Lactation	Not recommended; discontinue breastfeeding.
Pediatric Use	Safety and effectiveness not established (Not recommended).
Renal Impairment	Use with caution (Insufficient data for dose adjustment).

Use is approved for the adult population (18 years and older) when treating the specified malignant neoplasms. Older adults are eligible, but caution is advised due to the higher likelihood of reduced organ function.

Interactions with other medicines and products

This section describes officially documented interaction patterns of Docetaxel based on regulatory labeling.

---

Pharmacokinetic and Substance Interactions

Docetaxel is primarily metabolized by the cytochrome P450 3A4 (CYP3A4) enzyme system. Consequently, co-administration with other medicines that inhibit this enzyme can significantly alter Docetaxel exposure.

• CYP3A4 Inhibitors: Concurrent use with strong CYP3A4 inhibitors (such as ketoconazole or ritonavir) reduces Docetaxel clearance, leading to increased plasma concentrations and a higher risk of toxicity. Regulatory bodies recommend avoiding this combination.
• CYP3A4 Inducers: Conversely, co-administration with strong CYP3A4 inducers may accelerate clearance, potentially resulting in decreased systemic exposure.

---

Interaction-Related Restrictions and Cautions

Category	Regulatory Statement
Formulation Restriction	Contraindicated in patients with known severe hypersensitivity to Polysorbate 80, an excipient in some formulations.
Drug-Substance Caution	The alcohol content (ethanol) in the injectable solution may cause Central Nervous System (CNS) effects immediately following infusion.
Population-Specific	Contraindicated in patients with abnormal liver function (specific, elevated LFTs) due to a higher risk of severe complications from impaired drug clearance.

These interactions establish constraints based on drug-drug combinations and specific underlying physiological conditions that affect the body’s ability to clear the medicine.

Stabilization of Microtubules

Доцетаксел exerts its primary action by binding directly to the beta-tubulin subunit of microtubules. This interaction fundamentally modifies cytoskeletal dynamics by promoting tubulin assembly into microtubules and inhibiting their subsequent depolymerization (breakdown). The resulting physiological consequence is the prevention of the necessary reorganization and shortening of microtubules required for normal cellular processes.

---

Induction of Mitotic Arrest and Apoptosis

The stabilization of the microtubule network leads directly to the formation of a disorganized and overly stable mitotic spindle, preventing the proper alignment and separation of chromosomes. This severe spindle dysfunction arrests the cell cycle in the G2/M phase. This prolonged mitotic arrest triggers a molecular cascade that leads to apoptosis (programmed cell death) in rapidly dividing cells.

---

Interference with Cytoskeletal-Dependent Processes

Beyond mitosis, the drug's effect on microtubule stability influences other fundamental cellular activities, such as intracellular transport and the maintenance of cellular shape and motility. By disrupting the necessary dynamic restructuring of the cytoskeleton, this mechanism may influence processes related to cellular migration and morphology.

Docetaxel is administered exclusively by intravenous (IV) infusion under the supervision of a physician qualified in chemotherapy use in a specialized clinical setting. Administration follows a fixed, repeating cyclic schedule.

---

Dosing and Schedule

The treatment is typically administered every three weeks (q3Weeks), with Docetaxel given on Day 1 of the cycle. The dose is calculated using the patient's Body Surface Area (BSA) and expressed in mg/m^2. Standard regimens range from 60–100 mg/m^2 for monotherapy and 75 mg/m^2 when used in combination protocols. The infusion itself is administered over a fixed period of one hour.

---

Administration Protocol and Adjustments

Standard administration requires adherence to specific procedural steps. The concentrate must first be diluted to the final solution before administration. A key component of the protocol is the use of oral corticosteroids (such as dexamethasone) starting one day prior to the Docetaxel infusion.

Clinical protocols include rules for dose modification. Dose reduction or treatment deferral is utilized for patients who meet specific criteria for hepatic impairment (e.g., elevated liver enzymes and bilirubin) or who experience predefined systemic events. Treatment is generally deferred if a patient’s neutrophil count is below specific thresholds, ensuring the cyclic therapy proceeds only when appropriate.

Research evidence / Overview of studies for Доцетаксел

Evidence from Clinical Trials for Breast Cancer

This section will summarize the structure of the clinical research supporting Docetaxel's use in breast cancer, including the types of randomized trials conducted in both the early-stage (adjuvant) and advanced (metastatic) settings.

Docetaxel was studied for breast cancer across different disease stages. Researchers primarily conducted large Randomized Controlled Trials (RCTs) to compare Docetaxel-containing regimens against other standard approaches. These studies included adults with operable, node-positive disease and those whose cancer had progressed after receiving prior chemotherapy.

Outcomes Evaluated in Breast Cancer Studies

The primary focus of the research was on outcomes related to systemic or functional imbalance, specifically how long patients lived (Overall Survival, OS) and how long they remained free of the disease (Disease-Free Survival, DFS). Studies monitored tumor size changes, providing insight into short-term changes in tumor activity. The consistency of long-term outcomes for patients with certain low-risk characteristics is still being explored across all published data.

Evidence from Clinical Trials for Prostate Cancer

This section will outline the pivotal Phase III studies conducted for Docetaxel in metastatic, hormone-refractory prostate cancer, detailing the patient populations examined and the primary outcomes assessed.

Docetaxel was evaluated in several large, pivotal Phase III Randomized Controlled Trials (RCTs) focused on adult men with prostate cancer that had spread and was no longer responding to standard hormone therapy (known as castration-resistant metastatic prostate cancer, or mCRPC). Research examined high-level outcomes related to survival (OS) and patient-reported outcomes describing perceived discomfort (such as pain response and quality of life). Findings described a pattern of OS measurements across the treatment groups.

Areas of Research Uncertainty and Study Limitations

The evidence base is established for many approved uses, but limitations exist. Data are still emerging regarding the best sequencing of Docetaxel with many newer molecularly targeted agents, and comparative evidence is lacking in some treatment scenarios. Furthermore, the full range of patient-reported outcomes describing perceived discomfort and quality of life remain less characterized across every single regimen or indication. The evidence quality varies across studies, and some smaller trials provide limited information for long-term outcomes or rare subgroups.

Key Studies & References

1. Docetaxel Improves Survival in Node-Positive Early-Stage Breast Cancer Patients (BCIRG 001 Study analysis)
2. Phase III randomized trials of docetaxel in patients with metastatic breast cancer

Common questions about Доцетаксел (FAQ)

---

Q: How long after Docetaxel administration do side effects usually appear?

According to official product information, the timeline for adverse reactions varies. Serious reactions like hypersensitivity can be immediate. Neutropenia, which is a drop in white blood cell count, typically reaches its lowest point (nadir) around 7 days after the infusion. Fluid retention is often cumulative, meaning its severity can increase with each subsequent treatment cycle.

Q: Can Docetaxel cause joint or muscle pain?

Official regulatory lists of reported side effects indicate that both myalgia (muscle pain) and arthralgia (joint pain) have been experienced by patients receiving Docetaxel. These types of pain are known adverse reactions associated with the treatment.

Q: How long does Docetaxel stay in the body after infusion?

Pharmacokinetic studies summarized in official documents show that Docetaxel is eliminated from the body in a multi-step (triphasic) manner. While initial clearance is rapid, the terminal elimination half-life of the drug is reported to be approximately 11 hours or slightly longer. This means the substance is eliminated relatively slowly over time.

Q: Does Docetaxel affect the ability to have children in the future?

Official safety information indicates that Docetaxel may impair fertility. Non-clinical studies have described these potential effects on reproductive function. Official information suggests patients review the known risks to their reproductive function with a healthcare professional.

Q: Is it true that Docetaxel is used together with Trastuzumab?

Yes, according to official prescribing information, Docetaxel is indicated for use in combination with Trastuzumab. This specific combination is used for the treatment of certain types of breast cancer, as outlined in regulatory documents.

Q: How does Docetaxel affect the skin and nails?

Official adverse event lists detail several possible effects on the skin and nails. These include various skin reactions (such as rash or desquamation, which is peeling skin) and nail disorders (which can involve changes, discoloration, or loss of the nails). Alopecia (hair loss) is also a very common side effect.

Q: Can Docetaxel affect mood or cause depression?

Official product information indicates that depression has been reported as an adverse reaction during the post-marketing experience for Docetaxel. Mood changes are a side effect that may require attention from a healthcare professional.

Q: Can Docetaxel cause vision problems?

Yes, official safety documentation reports that Docetaxel may cause eye disorders. This includes a condition called Cystoid Macular Edema (CME), which is swelling in the retina. If this occurs, regulatory documentation indicates that treatment may need to be stopped.

Q: If I had cancer before, can I take Docetaxel again for a different type of tumor?

Official prescribing information shows that Docetaxel is indicated for treating several distinct cancers, such as breast, prostate, lung, and gastric cancer. This confirms that the drug can be used in different therapeutic settings. The appropriateness of sequential use for a different tumor type is based on the established, approved indications for the medicine.

Q: What does 'contraindications' mean for Docetaxel in the official instructions?

A contraindication is a specific situation in which a medicine must not be used because it carries a known risk of being harmful to the patient. For Docetaxel, official instructions list conditions like a history of severe hypersensitivity or having a neutrophil count below a specified threshold as contraindications.

Q: What precautions should be taken at home after Docetaxel infusion?

According to official patient counseling information, precautions may be necessary due to the risk of infection caused by a low white blood cell count (neutropenia). Protective measures related to careful hygiene and avoiding contact with sick individuals are commonly associated with preventing infection when blood counts are low.

How to Store and Dispose of Docetaxel

Docetaxel concentrate must be stored under specific, controlled conditions to maintain stability and integrity.

Storage Requirements

Unopened vials must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The product must be kept in its original container for protection from light. It is mandatory to keep the medicine out of the sight and reach of children. Specific formulations of the unopened concentrate should not be refrigerated as precipitation may occur.

Stability and Handling

• Multi-Dose Vials: After first use, multiple-dose vials may be stored for up to 28 days under refrigeration (2 C to 8 C) while protected from light.
• Single-Dose Vials: Any unused portion of a single-dose vial must be discarded immediately.

Disposal Instructions

Docetaxel is classified as a hazardous drug and a cytotoxic agent. Disposal of the unused product and all waste materials must be carried out according to local, regional, and national requirements for cytotoxic waste. The product must not be disposed of via household trash or wastewater systems.